Cognition Therapeutics schedules FDA meeting on Phase 3 endpoint for zervimesine in DLB psychosis
CGTX•Cognition Therapeutics will meet the FDA Division of Neurology on Oct. 20, 2026, to discuss endpoint analytics and statistics for a planned Phase 3 trial of zervimesine in dementia with Lewy bodies.
1. FDA meeting planned
Cognition Therapeutics will meet the FDA Division of Neurology on Oct. 20, 2026, in a Type C meeting. Discussions will focus on endpoint analytics and statistics for a planned Phase 3 trial of zervimesine in dementia with Lewy bodies.
